Takeda Pharmaceutical (TAK) EPS (Diluted) Growth (3y) (2020 - 2026)
Powered by 
Analysis
Takeda Pharmaceutical (TAK) EPS (Diluted) Growth (3y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.13 Bn | 625.38 Bn | 17.26 Bn | 5.00% |
| 2 | AbbVie | 442.39 Bn | 435.82 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 366.26 Bn | 359.12 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 266.58 Bn | 258.89 Bn | 11.24 Bn | 16.56% |
| 5 | Pfizer | 159.00 Bn | 147.30 Bn | 10.94 Bn | -28.10% |
| 6 | Sanofi | 52.39 Bn | 45.00 Bn | 10.79 Bn | -36.04% |
| 7 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 8 | Incyte | 25.41 Bn | 20.87 Bn | 1.57 Bn | 46.09% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 11.56% |
| 10 | Takeda Pharmaceutical | 2.61 Bn | -3.19 Bn | 5.10 Bn | 2.76% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.76% |
| Mar 31, 2026 | -0.19% |
| Dec 31, 2025 | -68.57% |
| Sep 30, 2025 | 47.72% |
| Jun 30, 2025 | 1.28% |
| Mar 31, 2025 | 116.75% |
| Dec 31, 2024 | -37.27% |
| Sep 30, 2024 | 50.00% |
| Jun 30, 2024 | -21.47% |
| Mar 31, 2024 | -29.97% |
| Dec 31, 2023 | 20.39% |
| Sep 30, 2023 | 273.13% |
| Jun 30, 2023 | -5.34% |
| Mar 31, 2023 | 268.44% |
| Sep 30, 2022 | 34.91% |
| Jun 30, 2022 | 98.40% |
| Mar 31, 2022 | -27.14% |
| Dec 31, 2021 | 38.23% |
| Sep 30, 2021 | -41.81% |
| Jun 30, 2021 | -4.31% |